How to Improve the Survival of Transplanted Mesenchymal Stem Cell in Ischemic Heart?

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Li, Liangpeng ^a   Chen, Xiongwen ^b   Wang, Wei Eric ^a   Zeng, Chunyu ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; ROSUVASTATIN; SIMVASTATIN;

CELL DIFFERENTIATION; CELL ENGINEERING; CELL SHEET; CELL SURVIVAL; CELL VIABILITY; CLINICAL EFFECTIVENESS; CORONARY VENOUS INFUSION; DNA MODIFICATION; EXTRACORPOREAL LITHOTRIPSY; HEART INFARCTION; HEART SURGERY; HUMAN; HYDROGEL; HYPEROXIA; HYPOXIA; INFUSION; ISCHEMIC HEART DISEASE; ISCHEMIC PRECONDITIONING; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PERIPHERAL INTRAVENOUS INFUSION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; SURVIVAL RATE; TIME; TOTAL QUALITY MANAGEMENT;

EID: 84949293824     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/9682757     Document Type: Review

References (134)

1. S. J. Jansen Of Lorkeers, J. E. C. Eding, H. M. Vesterinen et al., "Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies," Circulation Research, vol. 116, no. 1,pp. 80-86, 2015.
2. N. Kawaguchi and T. Nakanishi, "Cardiomyocyte regeneration," Cells, vol. 2, no. 1, pp. 67-82, 2013.
3. M. R. Rosen, R. J. Myerburg, D. P. Francis, G. D. Cole, and E. Marbán, "Translating stem cell research to cardiac disease therapies: pitfalls and prospects for improvement," Journal of the American College of Cardiology, vol. 64, no. 9, pp. 922-937, 2014.
4. I.-K. Ko and B.-S. Kim, "Mesenchymal stem cells for treatment of myocardial infarction," International Journal of Stem Cells, vol. 1, no. 1, pp. 49-54, 2008.
5. A. Farini, C. Sitzia, S. Erratico, M. Meregalli, and Y. Torrente, "Clinical applications of mesenchymal stem cells in chronic diseases," Stem Cells International, vol. 2014,Article ID 306573, 11 pages, 2014.
6. A. J. Friedenstein, R. K. Chailakhjan, and K. S. Lalykina, "The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells," Cell and Tissue Kinetics, vol. 3, no. 4, pp. 393-403, 1970.
7. P. A. Zuk, M. Zhu, H. Mizuno et al., "Multilineage cells from human adipose tissue: implications for cell-based therapies," Tissue Engineering, vol. 7, no. 2, pp. 211-228, 2001.
8. C. De Bari, F. Dell'Accio, P. Tylzanowski, and F. P. Luyten, "Multipotent mesenchymal stem cells from adult human synovial membrane," Arthritis and Rheumatism, vol. 44, no. 8, pp. 1928-1942, 2001.
9. F. Sabatini, L. Petecchia, M. Tavian, V. J. de Villeroché, G. A. Rossi, and D. Brouty-Boyé, "Human bronchial fibroblasts exhibit a mesenchymal stem cell phenotype and multilineage differentiating potentialities," Laboratory Investigation, vol. 85, no. 8, pp. 962-971, 2005.
10. H. R. Jang, J. H. Park, G. Y. Kwon et al., "Effect of preemptive treatment with human umbilical cord blood-derived mesenchymal stem cells on the development of renal ischemiareperfusion injury in mice," American Journal of Physiology. Renal Physiology, vol. 307, no. 10, pp. F1149-F1161, 2014.
11. N. J. Zvaifler, L. Marinova-Mutafchieva, G. Adams et al., "Mesenchymal precursor cells in the blood of normal individuals," Arthritis Research, vol. 2, no. 6, pp. 477-488, 2000.
12. Y.-S. Huang, I.-H. Li, S.-H. Chueh et al., "Mesenchymal stem cells from rat olfactory bulbs can differentiate into cells with cardiomyocyte characteristics," Journal of Tissue Engineering and Regenerative Medicine, 2013.
13. L. da Silva Meirelles, P. C. Chagastelles, and N. B. Nardi, "Mesenchymal stem cells reside in virtually all post-natal organs and tissues," Journal of Cell Science, vol. 119, no. 11, pp. 2204-2213, 2006.
14. A. H. Piersma, K. G. M. Brockbank, R. E. Ploemacher, E. van Vliet, K. M. Brakel-van Peer, and P. J. Visser, "Characterization of fibroblastic stromal cells from murine bone marrow," Experimental Hematology, vol. 13, no. 4, pp. 237-243, 1985.
15. E. Y. Plotnikov, T. G. Khryapenkova, A. K. Vasileva et al., "Cell-to-cell cross-talk between mesenchymal stem cells and cardiomyocytes in co-culture," Journal of Cellular andMolecular Medicine, vol. 12, no. 5, pp. 1622-1631, 2008.
16. C. Toma, M. F. Pittenger, K. S. Cahill, B. J. Byrne, and P. D. Kessler, "Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart," Circulation, vol. 105, no. 1, pp. 93-98, 2002.
17. S. Fazel, L. Chen, R. D. Weisel et al., "Cell transplantation preserves cardiac function after infarction by infarct stabilization: Augmentation by stem cell factor," The Journal ofThoracic and Cardiovascular Surgery, vol. 130, no. 5, pp. 1310. e1-1310. e10, 2005.
18. N. Noiseux, M. Gnecchi, M. Lopez-Ilasaca et al., "Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation,"MolecularTherapy, vol. 14,no. 6, pp. 840-850, 2006.
19. A. Keating, "Mesenchymal stromal cells: new directions," Cell Stem Cell, vol. 10, no. 6, pp. 709-716, 2012.
20. M. Dominici, K. Le Blanc, I. Mueller et al., "Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement," Cytotherapy, vol. 8, no. 4, pp. 315-317, 2006.
21. C. Nombela-Arrieta, J. Ritz, and L. E. Silberstein, "The elusive nature and function of mesenchymal stem cells," Nature Reviews: Molecular Cell Biology, vol. 12, no. 2, pp. 126-131, 2011.
22. R. A. Panepucci, J. L. C. Siufi,W. A. Silva Jr. et al., "Comparison of gene expression of umbilical cord vein and bone marrowderived mesenchymal stem cells," Stem Cells, vol. 22, no. 7, pp. 1263-1278, 2004.
23. R. H. Lee, B. Kim, I. Choi et al., "Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue," Cellular Physiology and Biochemistry, vol. 14, no. 4-6, pp. 311-324, 2004.
24. S. Tomita, R.-K. Li, R. D. Weisel et al., "Autologous transplantation of bone marrow cells improves damaged heart function," Circulation, vol. 100, no. 19, pp. II247-II256, 1999.
25. K. E. Hatzistergos, H. Quevedo, B. N. Oskouei et al., "Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation," Circulation Research, vol. 107, no. 7, pp. 913-922, 2010.
26. S. Wakitani, T. Saito, and A. I. Caplan, "Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine," Muscle & Nerve, vol. 18, no. 12, pp. 1417-1426, 1995.
27. S. Fazel, L. Chen, R. D. Weisel et al., "Cell transplantation preserves cardiac function after infarction by infarct stabilization: Augmentation by stem cell factor," Journal of Thoracic and Cardiovascular Surgery, vol. 130, no. 5, pp. 1310. e1-1310. e10, 2005.
28. H. Reinecke, E. Minami,W.-Z. Zhu, and M. A. Laflamme, "Cardiogenic differentiation and transdifferentiation of progenitor cells," Circulation Research, vol. 103, no. 10, pp. 1058-1071, 2008.
29. M. Z. Ratajczak, M. Kucia, T. Jadczyk et al., "Pivotal role of paracrine effects in stem cell therapies in regenerative medicine: can we translate stem cell-secreted paracrine factors and microvesicles into better therapeutic strategies," Leukemia, vol. 26, no. 6, pp. 1166-1173, 2012.
30. R. C. Scott, J. M. Rosano, Z. Ivanov et al., "Targeting VEGFencapsulated immunoliposomes to MI heart improves vascularity and cardiac function," The FASEB Journal, vol. 23, no. 10, pp. 3361-3367, 2009.
31. J. A. I. Virag, M. L. Rolle, J. Reece, S. Hardouin, E. O. Feigl, and C. E. Murry, "Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function," The American Journal of Pathology, vol. 171, no. 5, pp. 1431-1440, 2007.
32. E. Ruvinov, J. Leor, and S. Cohen, "The promotion ofmyocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction," Biomaterials, vol. 32, no. 2, pp. 565-578, 2011.
33. L. Huang, W. Ma, Y. Ma, D. Feng, H. Chen, and B. Cai, "Exosomes in mesenchymal stem cells, a new therapeutic strategy for cardiovascular diseases" International Journal of Biological Sciences, vol. 11, no. 2, pp. 238-245, 2015.
34. Y. Feng, W. Huang, M. Wani, X. Yu, andM. Ashraf, "Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targetingMecp2 via miR-22," PLoS ONE, vol. 9, no. 2,Article ID e88685, 2014.
35. B. Yu, M. Gong, Y. Wang et al., "Cardiomyocyte protection by gata-4 gene engineered mesenchymal stem cells is partially mediated by translocation of mir-221 in microvesicles," PLoS ONE, vol. 8, no. 8,Article ID e73304, 2013.
36. F. Arslan, R. C. Lai, M. B. Smeets et al., "Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury," Stem Cell Research, vol. 10, no. 3, pp. 301-312, 2013.
37. J. L. Spees, S. D. Olson, M. J. Whitney, and D. J. Prockop, "Mitochondrial transfer between cells can rescue aerobic respiration," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 5, pp. 1283-1288, 2006.
38. A. Acquistapace, T. Bru, P.-F. Lesault et al., "Human mesenchymal stem cells reprogram adult cardiomyocytes toward a progenitor-like state through partial cell fusion and mitochondria transfer," Stem Cells, vol. 29, no. 5, pp. 812-824, 2011.
39. B. E. Strauer, M. Brehm, T. Zeus et al., "Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction," Deutsche Medizinische Wochenschrift, vol. 126, pp. 932-938, 2001.
40. K. C. Wollert, G. P. Meyer, J. Lotz et al., "Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the boost randomised controlled clinical trial," The Lancet, vol. 364, no. 9429, pp. 141-148, 2004.
41. K. S. Telukuntla, V. Y. Suncion, I. H. Schulman, and J. M. Hare, "The advancing field of cell-based therapy: insights and lessons from clinical trials," Journal of the American Heart Association, vol. 2, no. 5, Article ID e000338, 2013.
42. J. M. Hare, J. E. Fishman, G. Gerstenblith et al., "Comparison of allogeneic vs autologous bonemarrow-derivedmesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial," The Journal of the AmericanMedical Association, vol. 308, no. 22, pp. 2369-2379, 2012.
43. J. Bartunek, A. Behfar, D. Dolatabadi et al., "Cardiopoietic stem cell therapy in heart failure: the c-cure (cardiopoietic stem cell therapy in heart failure) multicenter randomized trial with lineage-specified biologics," Journal of the American College of Cardiology, vol. 61, no. 23, pp. 2329-2338, 2013.
44. A. W. Heldman, D. L. DiFede, J. E. Fishman et al., "Transendocardialmesenchymal stem cells and mononuclear bonemarrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial," Journal of the American Medical Association, vol. 311, no. 1, pp. 62-73, 2014.
45. A. B. Mathiasen, A. A. Qayyum, E. Jorgensen et al., "Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: A randomized placebo-controlled trial (MSC-HF trial)," European Heart Journal, 2015.
46. S.-L. Chen, W.-W. Fang, F. Ye et al., "Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction,"The American Journal of Cardiology, vol. 94, no. 1, pp. 92-95, 2004.
47. A. E. Ting and W. Sherman, "Allogeneic stem cell transplantation for ischemic myocardial dysfunction," Current Opinion in Organ Transplantation, vol. 17, no. 6, pp. 675-680, 2012.
48. E. Martin-Rendon, S. J. Brunskill, C. J. Hyde, S. J. Stanworth, A. Mathur, and S. M. Watt, "Autologous bone marrow stem cells to treat acute myocardial infarction: A systematic review," European Heart Journal, vol. 29, no. 15, pp. 1807-1818, 2008.
49. K. Lunde, S. Solheim, S. Aakhus et al., "Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction," The New England Journal of Medicine, vol. 355, no. 12, pp. 1199-1209, 2006.
50. M. Gyöngyösi, J. Blanco, T. Marian et al., "Serial noninvasive in vivo positron emission tomographic tracking of percutaneously intramyocardially injected autologous porcine mesenchymal stem cells modified for transgene reporter gene expression," Circulation: Cardiovascular Imaging, vol. 1, no. 2, pp. 94-103, 2008.
51. L. M. McGinley, J. McMahon, A. Stocca et al., "Mesenchymal stem cell survival in the infarcted heart is enhanced by lentivirus vector-mediated heat shock protein 27 expression," Human GeneTherapy, vol. 24, no. 10, pp. 840-851, 2013.
52. M. Hofmann, K. C. Wollert, G. P. Meyer et al., "Monitoring of bone marrow cell homing into the infarcted human myocardium," Circulation, vol. 111, no. 17, pp. 2198-2202, 2005.
53. A. Facciabene, X. Peng, I. S. Hagemann et al., "Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells," Nature, vol. 475, no. 7355, pp. 226-230, 2011.
54. V. Schächinger, A. Aicher, N. Döbert et al., "Pilot trial on determinants of progenitor cell recruitment to the infarcted humanmyocardium," Circulation, vol. 118, no. 14, pp. 1425-1432, 2008.
55. H. Hamdi, A. Furuta, V. Bellamy et al., "Cell delivery: intramyocardial injections or epicardial deposition? A head-to-head comparison," Annals ofThoracic Surgery, vol. 87, no. 4, pp. 1196-1203, 2009.
56. A. Elsässer, K. Suzuki, S. Lorenz-Meyer, C. Bode, and J. Schaper, "The role of apoptosis inmyocardial ischemia: A critical appraisal," Basic Research in Cardiology, vol. 96, no. 3, pp. 219-226, 2001.
57. C. A. Thompson, B. A. Nasseri, J. Makower et al., "Percutaneous transvenous cellular cardiomyoplasty: A novel nonsurgical approach for myocardial cell transplantation," Journal of the American College of Cardiology, vol. 41, no. 11, pp. 1964-1971, 2003.
58. D. Hou, E. A.-S. Youssef, T. J. Brinton et al., "Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials," Circulation, vol. 112, no. 9, pp. I150-I156, 2005.
59. S. Fukushima, A. Varela-Carver, S. R. Coppen et al., "Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model," Circulation, vol. 115, no. 17, pp. 2254-2261, 2007.
60. H. Hamdi, V. Planat-Benard, A. Bel et al., "Epicardial adipose stem cell sheets results in greater post-infarction survival than intramyocardial injections," Cardiovascular Research, vol. 91, no. 3, pp. 483-491, 2011.
61. J. Leor, S. Aboulafia-Etzion, A. Dar et al., "Bioengineered cardiac grafts: A new approach to repair the infarcted myocardium" Circulation, vol. 102, no. 19, pp. III56-III61, 2000.
62. W. H. Zimmermann, C. Fink, D. Kralisch, U. Remmers, J. Weil, and T. Eschenhagen, "Three-dimensional engineered heart tissue from neonatal rat cardiac myocytes," Biotechnology and Bioengineering, vol. 68, no. 1, pp. 106-114, 2000.
63. W.-H. Zimmermann, I. Melnychenko, and T. Eschenhagen, "Engineered heart tissue for regeneration of diseased hearts," Biomaterials, vol. 25, no. 9, pp. 1639-1647, 2004.
64. J. Jin, S. I. Jeong, Y. M. Shin et al., "Transplantation of mesenchymal stem cells within a poly(lactide-co-epsilon-caprolactone) scaffold improves cardiac function in a rat myocardial infarction model," European Journal of Heart Failure, vol. 11, no. 2, pp. 147-153, 2009.
65. K. L. Christman, A. J. Vardanian, Q. Fang, R. E. Sievers, H. H. Fok, and R. J. Lee, "Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium," Journal of the American College of Cardiology, vol. 44, no. 3, pp. 654-660, 2004.
66. P. Maureira, P.-Y. Marie, F. Yu et al., "Repairing chronic myocardial infarction with autologous mesenchymal stem cells engineered tissue in rat promotes angiogenesis and limits ventricular remodeling," Journal of Biomedical Science, vol. 19, no. 1, article 93, 2012.
67. J. Leor, S. Tuvia, V. Guetta et al., "Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in swine," Journal of the American College of Cardiology, vol. 54, no. 11, pp. 1014-1023, 2009.
68. P. Sreejit and R. S. Verma, "Cardiogel supports adhesion, proliferation and differentiation of stem cells with increased oxidative stress protection," European Cells & Materials, vol. 21, pp. 107-121, 2011.
69. X. Bourges, P. Weiss, G. Daculsi, and G. Legeay, "Synthesis and general properties of silated-hydroxypropyl methylcellulose in prospect of biomedical use," Advances in Colloid and Interface Science, vol. 99, no. 3, pp. 215-228, 2002.
70. X. Li, J. Zhou, Z. Liu et al., "A PNIPAAm-based thermosensitive hydrogel containing SWCNTs for stem cell transplantation in myocardial repair," Biomaterials, vol. 35, no. 22, pp. 5679-5688, 2014.
71. C. Ceccaldi, R. Bushkalova, C. Alfarano et al., "Evaluation of polyelectrolyte complex-based scaffolds for mesenchymal stem cell therapy in cardiac ischemia treatment," Acta Biomaterialia, vol. 10, no. 2, pp. 901-911, 2014.
72. R. Ravichandran, J. R. Venugopal, S. Sundarrajan, S. Mukherjee, and S. Ramakrishna, "Cardiogenic differentiation ofmesenchymal stem cells on elastomeric poly (glycerol sebacate)/collagen core/shell fibers," World Journal of Cardiology, vol. 5, no. 3, pp. 28-41, 2013.
73. X.-Y. Li, T. Wang, X.-J. Jiang et al., "Injectable hydrogel helps bonemarrow-derivedmononuclear cells restore infarcted myocardium," Cardiology, vol. 115, no. 3, pp. 194-199, 2010.
74. X. Bourges, P. Weiss, A. Coudreuse, G. Daculsi, and G. Legeay, "General properties of silated hydroxyethylcellulose for potential biomedical applications," Biopolymers, vol. 63, no. 4, pp. 232-238, 2002.
75. C. A. Holladay, A. M. Duffy, X. Chen, M. V. Sefton, T. D. O'Brien, and A. S. Pandit, "Recovery of cardiac function mediated by MSC and interleukin-10 plasmid functionalised scaffold," Biomaterials, vol. 33, no. 5, pp. 1303-1314, 2012.
76. E. Mathieu, G. Lamirault, C. Toquet et al., "Intramyocardial delivery of mesenchymal stem cell-seeded hydrogel preserves cardiac function and attenuates ventricular remodeling after myocardial infarction," PLoS ONE, vol. 7, no. 12, Article ID e51991, 2012.
77. N. C. Panda, S. T. Zuckerman, O. O. Mesubi et al., "Improved conduction and increased cell retention in healed MI using mesenchymal stem cells suspended in alginate hydrogel," Journal of Interventional Cardiac Electrophysiology, vol. 41, no. 2, pp. 117-127, 2014.
78. X. Zhang, H. Wang, X. Ma et al., "Preservation of the cardiac function in infarcted rat hearts by the transplantation of adipose-derived stem cells with injectable fibrin scaffolds," Experimental Biology and Medicine, vol. 235, no. 12, pp. 1505-1515, 2010.
79. N. Frey, A. Linke, T. Suselbeck et al., "Intracoronary delivery of injectable bioabsorbable scaffold (ik-5001) to treat left ventricular remodeling after st-elevationmyocardial infarction: A firstin-man study," Circulation: Cardiovascular Interventions, vol. 7, no. 6, pp. 806-812, 2014.
80. M. Araña, J. J. Gavira, E. Peña et al., "Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipigmodels of chronicmyocardial infarction," Biomaterials, vol. 35, no. 1, pp. 143-151, 2014.
81. J. H. Li, N. Zhang, and J. A. Wangi, "Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy," Journal of Endocrinological Investigation, vol. 31, no. 2, pp. 103-110, 2008.
82. X. Hu, S. P. Yu, J. L. Fraser et al., "Transplantation of hypoxiapreconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis," Journal of Thoracic and Cardiovascular Surgery, vol. 135, no. 4, pp. 799-808, 2008.
83. L. Wang, X. Hu, W. Zhu et al., "Increased leptin by hypoxicpreconditioning promotes autophagy of mesenchymal stem cells and protects them from apoptosis," Science China Life Sciences, vol. 57, no. 2, pp. 171-180, 2014.
84. U. Saini, R. J. Gumina, B. Wolfe, M. L. Kuppusamy, P. Kuppusamy, and K. D. Boudoulas, "Preconditioning mesenchymal stem cells with caspase inhibition and hyperoxia prior to hypoxia exposure increases cell proliferation," Journal of Cellular Biochemistry, vol. 114, no. 11, pp. 2612-2623, 2013.
85. F. Figeac, P.-F. Lesault, O. Le Coz et al., "Nanotubular crosstalk with distressed cardiomyocytes stimulates the paracrine repair function of mesenchymal stem cells," Stem Cells, vol. 32, no. 1, pp. 216-230, 2014.
86. J. L. Herrmann, Y. Wang, A. M. Abarbanell, B. R. Weil, J. Tan, and D. R. Meldrum, "Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection," Shock, vol. 33, no. 1, pp. 24-30, 2010.
87. B. Xu, Y. Luo, Y. Liu, B. Y. Li, and Y. Wang, "Platelet-derived growth factor-BB enhances MSC-mediated cardioprotection via suppression of miR-320 expression," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 308, no. 9, pp. H980-H989, 2015.
88. S. Filip, J. Mokry, J. Horacek, and D. English, "Stem cells and the phenomena of plasticity and diversity: A limiting property of carcinogenesis," Stem Cells and Development, vol. 17, no. 6, pp. 1031-1038, 2008.
89. Q. Mao, C. Lin, J. Gao et al., "Mesenchymal stem cells overexpressing integrin-linked kinase attenuate left ventricular remodeling and improve cardiac function after myocardial infarction," Molecular and Cellular Biochemistry, vol. 397, no. 1-2, pp. 203-214, 2014.
90. W. Li,N. Ma, L.-L. Ong et al., "Bcl-2 engineered MSCs inhibited apoptosis and improved heart function," Stem Cells, vol. 25, no. 8, pp. 2118-2127, 2007.
91. S. Y. Lim, Y. S. Kim, Y. Ahn et al., "The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarctionmodel," Cardiovascular Research, vol. 70,no. 3, pp. 530-542, 2006.
92. M. Gnecchi, H. He, N. Noiseux et al., "Evidence supporting paracrine hypothesis for Akt-modifiedmesenchymal stem cellmediated cardiac protection and functional improvement," The FASEB Journal, vol. 20, no. 6, pp. 661-669, 2006.
93. S. Jiang, H. K. Haider, N. M. Idris, A. Salim, and M. Ashraf, "Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair," Circulation Research, vol. 99, no. 7, pp. 776-784, 2006.
94. X. Wang, T. Zhao, W. Huang et al., "Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors," Stem Cells, vol. 27, no. 12, pp. 3021-3031, 2009.
95. M. Mirotsou, Z. Zhang, A. Deb et al., "Secreted frizzled related protein 2 (Sfrp2) is the keyAkt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 5, pp. 1643-1648, 2007.
96. L. Fan, C. Lin, S. Zhuo et al., "Transplantation with survivinengineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction," European Journal of Heart Failure, vol. 11, no. 11, pp. 1023-1030, 2009.
97. Y. L. Tang, Y. Tang, Y. C. Zhang, K. Qian, L. Shen, and M. I. Phillips, "Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector," Journal of the American College of Cardiology, vol. 46, no. 7, pp. 1339-1350, 2005.
98. J. Cho, P. Zhai, Y. Maejima, and J. Sadoshima, "Myocardial injection with GSK-3-overexpressing bone marrow-derived mesenchymal stem cells attenuates cardiac dysfunction after myocardial infarction," Circulation Research, vol. 108, no. 4, pp. 478-489, 2011.
99. S. H. Ranganath, O. Levy, M. S. Inamdar, and J. M. Karp, "Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease," Cell Stem Cell, vol. 10, no. 3, pp. 244-258, 2012.
100. J. Huang, Z. Zhang, J. Guo et al., "Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium," Circulation Research, vol. 106, no. 11, pp. 1753-1762, 2010.
101. J. Tang, J. Wang, L. Guo et al., "Mesenchymal stem cells modified with stromal cell-derived factor 1 improve cardiac remodeling via paracrine activation of hepatocyte growth factor in a ratmodel ofmyocardial infarction,"Molecules andCells, vol. 29, no. 1, pp. 9-19, 2010.
102. W. E. Wang, D. Yang, L. Li et al., "Prolyl hydroxylase domain protein 2 silencing enhances the survival and paracrine function of transplanted adipose-derived stem cells in infarcted myocardium," Circulation Research, vol. 113, no. 3, pp. 288-300, 2013.
103. H. Li, S. Zuo, Z. He et al., "Paracrine factors released by GATA-4 overexpressed mesenchymal stem cells increase angiogenesis and cell survival," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 299, no. 6, pp. H1772-H1781, 2010.
104. F. Huang, M.-L. Li, Z.-F. Fang et al., "Overexpression of MicroRNA-1 improves the efficacy of mesenchymal stem cell transplantation after myocardial infarction," Cardiology, vol. 125, no. 1, pp. 18-30, 2013.
105. J. Xu, Z. Huang, L. Lin et al., "miR-210 over-expression enhances mesenchymal stem cell survival in an oxidative stress environment through antioxidation and c-Met pathway activation," Science China. Life Sciences, vol. 57, no. 10, pp. 989-997, 2014.
106. A. P. Beltrami, L. Barlucchi, D. Torella et al., "Adult cardiac stem cells are multipotent and support myocardial regeneration," Cell, vol. 114, no. 6, pp. 763-776, 2003.
107. R. Bolli, A. R. Chugh, D. D'Amario et al., "Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial," The Lancet, vol. 378, no. 9806, pp. 1847-1857, 2011.
108. R. Mazhari and J. M. Hare, "Mechanisms of action ofmesenchymal stem cells in cardiac repair: potential influences on the cardiac stemcell niche," Nature Clinical Practice Cardiovascular Medicine, vol. 4, supplement 1, pp. S21-S26, 2007.
109. B. N. Oskouei, G. Lamirault, C. Joseph et al., "Increasedpotency of cardiac stem cells comparedwith bone marrowmesenchymal stem cells in cardiac repair," Stem Cells Translational Medicine, vol. 1, no. 2, pp. 116-124, 2012.
110. A. R. Williams, K. E. Hatzistergos, B. Addicott et al., "Enhanced effect of combining human cardiac stemcells and bonemarrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction," Circulation, vol. 127, no. 2, pp. 213-223, 2013.
111. A. Facciabene, G. T. Motz, and G. Coukos, "T-regulatory cells: key players in tumor immune escape and angiogenesis," Cancer Research, vol. 72, no. 9, pp. 2162-2171, 2012.
112. Y. Zhou, A. K. Singh, R. F. Hoyt Jr. et al., "Regulatory T cells enhance mesenchymal stem cell survival and proliferation following autologous cotransplantation in ischemicmyocardium," The Journal ofThoracic and Cardiovascular Surgery, vol. 148, no. 3, pp. 1131-1137, 2014.
113. Y.-J. Yang, J.-L. Zhao, S.-J. You et al., "Post-infarction treatment with simvastatin reduces myocardial no-reflow by opening of the KATP channel," European Journal of Heart Failure, vol. 9, no. 1, pp. 30-36, 2007.
114. C. P. Sparrow, C. A. Burton, M. Hernandez et al., "Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 1, pp. 115-121, 2001.
115. B. Assmus, C. Urbich, A. Aicher et al., "HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes," Circulation Research, vol. 92, no. 9, pp. 1049-1055, 2003.
116. B. Kwak, F. Mulhaupt, S. Myit, and F. Mach, "Statins as a newly recognized type of immunomodulator," Nature Medicine, vol. 6, no. 12, pp. 1399-1402, 2000.
117. J.-D. Luo, F. Xie, W.-W. Zhang, X.-D. Ma, J.-X. Guan, and X. Chen, "Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes," British Journal of Pharmacology, vol. 132, no. 1, pp. 159-164, 2001.
118. Y.-J. Yang, H.-Y. Qian, J. Huang et al., "Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29,no. 12, pp. 2076-2082, 2009.
119. Z. Zhang, S. Li, M. Cui et al., "Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways," Basic Research in Cardiology, vol. 108, no. 2, article 333, 2013.
120. X. Hu, J. Wang, J. Chen et al., "Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction," European Journal of Cardio-Thoracic Surgery, vol. 31, no. 3, pp. 438-443, 2007.
121. S. Zhang, A. Sun, D. Xu et al., "Impact of timing on efficacy and safety of intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: A pooled subgroup analysis of randomized controlled trials," Clinical Cardiology, vol. 32, no. 8, pp. 458-466, 2009.
122. Y. Yang, F. M. V. Rossi, and E. E. Putnins, "Ex vivo expansion of rat bone marrowmesenchymal stromal cells on microcarrier beads in spin culture," Biomaterials, vol. 28, no. 20, pp. 3110-3120, 2007.
123. R. Sarugaser, L. Hanoun, A. Keating, W. L. Stanford, and J. E. Davies, "Human mesenchymal stem cells self-renew and differentiate according to a deterministic hierarchy," PLoS ONE, vol. 4, no. 8, Article ID e6498, 2009.
124. A. Aicher, C. Heeschen, K.-I. Sasaki, C. Urbich, A. M. Zeiher, and S. Dimmeler, "Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: A new modality to increase efficacy of cell therapy in chronic hind limb ischemia," Circulation, vol. 114, no. 25, pp. 2823-2830, 2006.
125. B. Assmus, D. H. Walter, F. H. Seeger et al., "Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial," Journal of the American Medical Association, vol. 309, no. 15, pp. 1622-1631, 2013.
126. X. Liang, Y. Ding, Y. Zhang, H.-F. Tse, and Q. Lian, "Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives," Cell Transplantation, vol. 23, no. 9, pp. 1045-1059, 2014.
127. T. Wang, X.-J. Jiang, Q.-Z. Tang et al., "Bone marrow stem cells implantation with -cyclodextrin/MPEG-PCL-MPEG hydrogel improves cardiac function aftermyocardial infarction," Acta Biomaterialia, vol. 5, no. 8, pp. 2939-2944, 2009.
128. N. Tano, T. Narita, M. Kaneko et al., "Epicardial placement of mesenchymal stromal cell-sheets for the treatment of ischemic cardiomyopathy; in vivo proof-of-concept study," Molecular Therapy, vol. 22, pp. 1864-1871, 2014.
129. Q. Zhang, H. Wang, Y.-J. Yang et al., "Atorvastatin treatment improves the effects of mesenchymal stem cell transplantation on acute myocardial infarction: the role of the RhoA/ROCK/ERK pathway," International Journal of Cardiology, vol. 176, no. 3, pp. 670-679, 2014.
130. Y. Wang, C. Li, K. Cheng et al., "Activation of liver X receptor improves viability of adipose-derived mesenchymal stem cells to attenuate myocardial ischemia injury through TLR4/NFkappaB and Keap-1/Nrf-2 signaling pathways," Antioxidants & Redox Signaling, vol. 21, no. 18, pp. 2543-2557, 2014.
131. Z. Zhang,D. Liang, X. Gao et al., "Selective inhibition of inositol hexakisphosphate kinases (IP6Ks) enhances mesenchymal stem cell engraftment and improves therapeutic efficacy for myocardial infarction," Basic Research in Cardiology, vol. 109, article417, 2014.
132. D. Han, W. Huang, S. Ma et al., "Ghrelin improves functional survival of engrafted adipose-derived mesenchymal stem cells in ischemic heart through pi3k/akt signaling pathway," BioMed Research International, vol. 2015, Article ID 858349, 12 pages, 2015.
133. B. Huang, J. Qian, J. Ma et al., "Myocardial transfection of hypoxia-inducible factor-1 and co-transplantation of mesenchymal stem cells enhance cardiac repair in rats with experimental myocardial infarction," Stem Cell Research & Therapy, vol. 5, article 22, 2014.
134. T. Deuse, C. Peter, P. W. M. Fedak et al., "Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acutemyocardial infarction," Circulation, vol. 120, no. 1,pp. S247-S254, 2009.